Healthcare Gainers: ISIS Pharmaceuticals, (NASDAQ:ISIS), BioMarin Pharmaceutical (NASDAQ:BMRN), Cubist Pharmaceuticals (NASDAQ:CBST), Repligen (NASDAQ:RGEN), bluebird bio (NASDAQ:BLUE)

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced it has earned a $10 million milestone payment from Biogen Idec associated with the validation of an undisclosed target to treat a neurological disorder. This is the first milestone payment under Isis’ and Biogen Idec’s 2013 strategic collaboration to advance the treatment of neurological disorders. This collaboration combines Biogen Idec’s expertise in neurology with Isis’ leadership in antisense technology to develop novel therapies to treat neurological disorders and is the fourth collaboration between the two companies. ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) net profit margin is -69.60% and weekly performance is 9.01%. On last trading day company shares ended up $36.66. Analysts mean target price for the company is $43.56. ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) distance from 50-day simple moving average is 22.60%.

BioMarin Pharmaceutical (NASDAQ:BMRN) was upgraded by research analysts at Credit Suisse from a “neutral” rating to an “outperform” rating in a report released on Monday. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares advanced 5.90% in last trading session and ended the day on $66.09. BMRN Gross Margin is 82.90% and its return on assets is -8.90%. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) quarterly performance is -10.60%.

Cubist Pharmaceuticals Inc. won US regulatory approval Friday to sell a new antibiotic that fights hard-to-treat skin infections caused by Gram-positive bacteria, including  methicillin-resistant Staphylococcus aureus, known as MRSA, a growing public health threat. Cubist Pharmaceuticals Inc (NASDAQ:CBST) shares moved up 5.38% in last trading session and was closed at $72.24, while trading in range of $70.30-$72.38. Cubist Pharmaceuticals Inc (NASDAQ:CBST) year to date performance is 4.89%.

Repligen Corp. (NASDAQ:RGEN) had its price objective hosited by Jefferies Group from $20.00 to $22.00 in a report released on Wednesday. Jefferies Group currently has a buy rating on the stock. Repligen Corporation (NASDAQ:RGEN) ended the last trading day at $21.98. Company weekly volatility is calculated as 3.98% and price to cash ratio as 9.95. Repligen Corporation (NASDAQ:RGEN) showed a positive weekly performance of 11.23%.

bluebird bio Inc. (NASDAQ:BLUE) announced initial positive clinical data from its HGB-205 clinical study of its LentiGlobin BB305 product candidate in beta-thalassemia major subjects on Saturday. bluebird bio Inc (NASDAQ:BLUE) weekly performance is 56.04%. On last trading day company shares ended up $40.71. Analysts mean target price for the company is $49.75. bluebird bio Inc (NASDAQ:BLUE) distance from 50-day simple moving average is 76.75%.